Investigating the mechanism by which SMAD3 induces PAX6 transcription to promote the development of non-small cell lung cancer

[1]  K. Miyazono,et al.  Long noncoding RNA NORAD regulates transforming growth factor‐β signaling and epithelial‐to‐mesenchymal transition‐like phenotype , 2018, Cancer science.

[2]  E. Richardsen,et al.  Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer , 2018, Scientific Reports.

[3]  Gang Li,et al.  MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Y. Huang,et al.  Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non–Small Cell Lung Cancer , 2017, Technology in cancer research & treatment.

[5]  G. Zhai,et al.  SMAD3 Is Upregulated in Human Osteoarthritic Cartilage Independent of the Promoter DNA Methylation , 2016, The Journal of Rheumatology.

[6]  A. Bode,et al.  244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells , 2015, Oncotarget.

[7]  Hui Li,et al.  MicroRNA-7 inhibits the malignant phenotypes of non‑small cell lung cancer in vitro by targeting Pax6. , 2015, Molecular medicine reports.

[8]  Xiangxian Zhang,et al.  Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer. , 2015, International journal of clinical and experimental pathology.

[9]  Xiangdong Li,et al.  Ski prevents TGF-β-induced EMT and cell invasion by repressing SMAD-dependent signaling in non-small cell lung cancer. , 2015, Oncology reports.

[10]  Shu-Lin Liu,et al.  Characterization of SMAD3 Gene Variants for Possible Roles in Ventricular Septal Defects and Other Congenital Heart Diseases , 2015, PloS one.

[11]  L. Tanoue,et al.  Lung cancer screening. , 2015, American journal of respiratory and critical care medicine.

[12]  D. Dhall,et al.  Comparison of PAX6 and PAX8 as Immunohistochemical Markers for Pancreatic Neuroendocrine Tumors , 2015, Endocrine pathology.

[13]  P. Iyengar,et al.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  X. Chen,et al.  Effects of Smad3 on the proliferation and steroidogenesis in human ovarian luteinized granulosa cells , 2014, IUBMB life.

[15]  T. Spector,et al.  SMAD3 Is Associated with the Total Burden of Radiographic Osteoarthritis: The Chingford Study , 2014, PloS one.

[16]  Lei Zhan,et al.  Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-β/Smad signaling in NSCLC cells with high metastatic potential. , 2014, International journal of oncology.

[17]  Yue Wang,et al.  Downregulation of PAX6 by shRNA Inhibits Proliferation and Cell Cycle Progression of Human Non-Small Cell Lung Cancer Cell Lines , 2014, PloS one.

[18]  Yuehui Li,et al.  PAX6, a Novel Target of microRNA-7, Promotes Cellular Proliferation and Invasion in Human Colorectal Cancer Cells , 2014, Digestive Diseases and Sciences.

[19]  B. Loo,et al.  American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. , 2012, Chest.

[20]  R. Ashery-Padan,et al.  Pax6: A multi-level regulator of ocular development , 2012, Progress in Retinal and Eye Research.

[21]  D. Carbone,et al.  Smoking Attenuates Transforming Growth Factor-β–Mediated Tumor Suppression Function through Downregulation of Smad3 in Lung Cancer , 2012, Cancer Prevention Research.

[22]  J. Jonas,et al.  Pax6 regulates proliferation and apoptosis of human retinoblastoma cells. , 2011, Investigative ophthalmology & visual science.

[23]  Peter Devilee,et al.  Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers , 2010, Breast Cancer Research.

[24]  Rajnikant Mishra,et al.  Interaction of Pax6 with SPARC and p53 in Brain of Mice Indicates Smad3 Dependent Auto-regulation , 2010, Journal of Molecular Neuroscience.

[25]  Terje Johansen,et al.  The MH1 domain of Smad3 interacts with Pax6 and represses autoregulation of the Pax6 P1 promoter , 2007, Nucleic acids research.